IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile
IP Group - visionary ventures

@ipgroupplc

Accelerating the impact of science for a better future with @ParkwalkAdvisor & @KikoVentures - @nanopore @FLFusion @FeaturespaceLtd #backinginnovation🧬🧪🔬🔭

ID: 335199434

linkhttp://www.ipgroupplc.com calendar_today14-07-2011 09:24:37

3,3K Tweet

5,5K Followers

2,2K Following

The Money Maze Podcast (@themoneymazepod) 's Twitter Profile Photo

📈Greg Smith, CEO of IP Group - visionary ventures, in conversation with the Money Maze Curated Podcast about world class tech innovation in the UK and more Full interview out tomorrow via moneymazepodcast.com! #Finance #Investing #Economics #Business #AssetManagement #ad #Podcast #Interview

📈Greg Smith, CEO of <a href="/IPGroupplc/">IP Group - visionary ventures</a>, in conversation with the Money Maze Curated Podcast about world class tech innovation in the UK and more

Full interview out tomorrow via moneymazepodcast.com!

#Finance #Investing #Economics #Business #AssetManagement #ad #Podcast #Interview
IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

Our 2024 Annual Report is now available to read.🔬🧪🧬 At IP Group, we understand science. We understand its impact today and its potential to shape the future. We aim to accelerate the impact of science for a better future. 🔗Read the full report: bit.ly/4jg7gnZ

Our 2024 Annual Report is now available to read.🔬🧪🧬

At IP Group, we understand science. We understand its impact today and its potential to shape the future.

We aim to accelerate the impact of science for a better future.

🔗Read the full report: bit.ly/4jg7gnZ
The Money Maze Podcast (@themoneymazepod) 's Twitter Profile Photo

📈Today we welcome Greg Smith, CEO of IP Group - visionary ventures . He discusses: ✅ Why UK innovation remains world-class, and where to find it ✅ Their aim to help cure rheumatoid arthritis and hitherto deadly lung infections ✅ Automating airports, ports and warehouses via cutting edge AI

IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

Our 2024 Impact Report is now available to read.🔬🧪🧬 Impact is at the heart of what we do, and why we were first established. We seek, through our investments, to have a tangible and positive impact on the world around us. Read the full report: bit.ly/4jxyUfE

Our 2024 Impact Report is now available to read.🔬🧪🧬
 
Impact is at the heart of what we do, and why we were first established. We seek, through our investments, to have a tangible and positive impact on the world around us. 
 
Read the full report: bit.ly/4jxyUfE
IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

💡Ahead of #WorldIPDay tomorrow we are excited to spotlight portfolio company Mixergy in our latest Case Study. 🔎 Read more about their journey and our role in supporting their growth: bit.ly/3EKZvqT

IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

🔬Life Sciences portfolio company Artios has a pipeline of novel cancer therapies in development that target DNA Damage Response (DDR) pathways, to destroy certain cancers that are difficult to treat. Read more on page 6 of our Impact Report: bit.ly/4jxyUfE

IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

👏 A huge congratulations to Australian portfolio company ElectraLith, which was selected a top innovator by the World Economic Forum! 🏆Electralith is a winner of the highly prestigious Sustainable Mining: Mining the Unmined Challenge. Read more: bit.ly/454TRL6

👏 A huge congratulations to Australian portfolio company ElectraLith, which was selected a top innovator by the <a href="/wef/">World Economic Forum</a>! 
 
🏆Electralith is a winner of the highly prestigious Sustainable Mining: Mining the Unmined Challenge. 

Read more: bit.ly/454TRL6
IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

📚Deeptech portfolio company SAM Labs is an award-winning startup that is transforming K-12 STEAM education to positively impact the learning experience for students globally. Read more in the Case Study on page 7 of our Impact Report: bit.ly/4jxyUfE

IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

Our latest newsletter is now live, featuring news from the Group and portfolio companies First Light Fusion and Lumai. Read here: bit.ly/42WkK2u Sign up to receive our newsletter: bit.ly/444qDHW

Our latest newsletter is now live, featuring news from the Group and portfolio companies First Light Fusion and Lumai.

Read here: bit.ly/42WkK2u

Sign up to receive our newsletter: bit.ly/444qDHW
IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

✨Cleantech portfolio company Hysata is redefining the economics of green hydrogen by manufacturing electrolysers with the world’s highest efficiency, which will enable the lowest Levelised Cost of Hydrogen. Read more on page 8 of our Impact Report: bit.ly/4jxyUfE

Hinge Health (@hingehealth) 's Twitter Profile Photo

A new era begins for Hinge Health. Over a decade ago, we set out to reimagine healthcare—today, we celebrate going public as $HNGE on the NYSE 🏛. Thank you to our members, partners, clients & team who made this day possible.

IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

Congratulations to Dan Perez, Gabriel Mecklenburg & team on the IPO of Hinge Health. Great to see such strong support for the IPO on the New York Stock Exchange. IP Group backed Dan from the very beginning as he showed such entrepreneurial spirit and tenacity. Having made more

IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

💬“Great companies are powered by the passion and authenticity of their originator.” Last week's IPO of portfolio company Hinge Health marks a significant milestone in a journey that began way back in 2012. In our latest Insight piece, Robert Trezona, Partner at IP Group - visionary ventures

IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

🧬📰 Great news today from portfolio company Iksuda Therapeutics, which has announced the dosing of its first patient with IKS03, a CD19-directed antibody drug conjugate (ADC), in a phase 1, first-in-human, clinical trial in patients with advanced B cell non-Hodgkin lymphoma. 👉Read more:

🧬📰 Great news today from portfolio company <a href="/IksudaT/">Iksuda Therapeutics</a>, which has announced the dosing of its first patient with IKS03, a CD19-directed antibody drug conjugate (ADC), in a phase 1, first-in-human, clinical trial in patients with advanced B cell non-Hodgkin lymphoma.

👉Read more:
IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

Congratulations to portfolio company AccelerComm, which has closed a $15m funding round. We are proud to have led the round (which included from funds managed/advised on behalf of Parkwalk and Hostplus). The capital will be used to further develop and accelerate

IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

Congratulations to portfolio company AccelerComm, which this week announced the closing of a $15m funding round. We are proud to have led the round (which included from funds managed/advised on behalf of Parkwalk and Hostplus). Read more: bit.ly/3ZbwYlD

IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

Today is #WorldEnvironmentDay, with the focus being #BeatPlasticPollution♻️✨ Vytal, an asset in our cleantech platform, Kiko Ventures is the largest digital re-use system for food packaging in take-away & delivery & is now operational in 23 countries. Their work is a

IP Group - visionary ventures (@ipgroupplc) 's Twitter Profile Photo

🧬 A warm welcome to Dr Robert Tansley as portfolio company Microbiotica Ltd ’s Chief Medical Officer. The appointment comes at a key time for the company with its two lead programmes progressing through Phase 1 clinical trials in immuno-oncology (MB097 for advanced melanoma),

🧬 A warm welcome to Dr Robert Tansley as portfolio company <a href="/MicrobioticaLtd/">Microbiotica Ltd</a> ’s Chief Medical Officer.

The appointment comes at a key time for the company with its two lead programmes progressing through Phase 1 clinical trials in immuno-oncology (MB097 for advanced melanoma),